Aspirin

Platelets, crucial for blood clotting, face classification debates but remain lifesavers. Current platelet function assessment methods are inadequate, prompting new technologies focusing on force measurement. Innovations like Stasys Medical Corporation's platform and Mechano-Cas12a Assisted Tension Sensor (MCATS) aim to provide more precise, less invasive diagnostics, potentially revolutionizing trauma and surgical care.

Articles discuss ischemic stroke in young adults, risk factors, mimics, and management, including global perspectives, pediatric stroke, and cerebrovascular complications of sickle cell disease.

Despite no cure for the common cold, the US Cold & Cough Remedies market is projected to generate $11.19 billion in 2024. The FDA proposed removing phenylephrine, a common but ineffective OTC cold medicine ingredient, after a 17-year petition. Medical experts advise against using phenylephrine alone and recommend nasal saline, honey for cough, and hydration for cold relief. Prevention, including handwashing and avoiding face touching, is emphasized as the best strategy against colds.

Fanaroff: Research grants from American Heart Association and National Institutes of Health; consulting fees from Abbott Laboratories. Vora: Consulting fees from Medtronic. Mehran: Institutional research grants from AstraZeneca, Bayer, Beth Israel Deaconess, Bristol Myers Squibb/Sanofi, CSL Behring, Eli Lilly/Daiichi Sankyo, Medtronic, Novartis, OrbusNeich; consulting fees from Boston Scientific, Abbott Vascular, Medscape, Siemens Medical Solutions, Roivant Sciences Inc, Sanofi; consulting (no fees) for Regeneron Pharmaceuticals Inc; institutional consulting fees from Abbott Vascular, Spectranetics/Phillips/Volcano Corporation, Bristol Myers Squibb, Novartis, Watermark Research; Executive committee member for Janssen Pharmaceuticals and Bristol Myers Squibb; <1% equity in Claret Medical and Elixir Medical. Granger: Research grants from Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, Armetheon, AstraZeneca, US Food and Drug Administration, GlaxoSmithKline, The Medicines Company, Medtronic Foundation, Medtronic Inc, Novartis; consulting fees from Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, Abbvie, Armetheon, AstraZeneca, Eli Lilly, Gilead, GlaxoSmithKline, Hoffmann-La Roche, The Medicines Company, National Institutes of Health, Novartis, Sirtex, Verseon, Apple, Medscape, LLC, Merck, Novo Nordisk, Roche Diagnostics, Rho Pharmaceuticals. Goodman: Research grant support and/or speaker/consulting honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Daiichi-Sankyo, Eli Lilly, Esperion, Fenix Group International, Ferring Pharmaceuticals, GlaxoSmithKline, HLS Therapeutics, Janssen/Johnson & Johnson, Luitpold Pharmaceuticals, Matrizyme, Merck, Novartis, Novo Nordisk A/C, Pfizer, Regeneron, Sanofi, Servier, Tenax Therapeutics, Heart and Stroke Foundation of Ontario/University of Toronto, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Duke Clinical Research Institute, PERFUSE. Aronson: Employee of Bristol Myers Squibb. Windecker: Institutional research and educational grants from Abbott, Amgen, Bayer, BMS, CSL Behring, Boston Scientific, Biotronik, Edwards Lifesciences, Medtronic, Polares, Sinomed. Alexander: Research grants from Bristol Myers Squibb, Boehringer Ingelheim, AstraZeneca, CryoLife, CSL Behring, US Food and Drug Administration, National Institutes of Health, Sanofi, VoluMetrix; consulting fees from Pfizer, Bristol Myers Squibb, AbbVie Pharmaceuticals, CSL Behring, Novo Nordisk, Portola Pharmaceuticals, Quantum Genomics, Teikoku Pharmaceuticals, VA Cooperative Studies, Zafgen. Lopes: Research grants from Bristol Myers Squibb, Pfizer, Amgen, Inc, GlaxoSmithKline, Medtronic PLC, Sanofi Aventis; consulting fees from Bristol Myers Squibb, Pfizer, Boehringer Ingelheim, Bayer AG. The other authors report no conflicts.

Dr. Anmol Kapoor founded BioAro to revolutionize healthcare through genomics, leveraging AI and machine learning. BioAro achieved 100% accuracy in whole genome sequencing interpretation, expanding globally with offices in Europe and the Middle East. The company is now exploring partnerships in Taiwan for hardware integration and is spinning off companies in sports genomics and longevity medicine.

Christian Ruff, MD, MPH, presented results from the AZALEA-TIMI 71 trial, showing abelacimab (Anthos) significantly reduced bleeding in high-risk patients with atrial fibrillation and atherosclerotic cardiovascular disease compared to rivaroxaban. Abelacimab targets factor 11 in the blood clotting cascade, reducing bad clots without inhibiting healing clots, leading to a 60-70% reduction in bleeding. Future research includes the LILAC-TIMI 76 trial to establish abelacimab's efficacy in reducing stroke in high-risk patients.

Article references various clinical trials and studies on stroke prevention, treatment, and management, including trials on blood pressure lowering, antiplatelet therapy, and the use of routine health data in clinical trials.

Fluctuating cholesterol levels without medication changes may indicate higher dementia risk, according to a study using ASPREE trial data. High variability in total cholesterol and LDL-C was linked to increased dementia and cognitive decline, while triglyceride and HDL-C fluctuations were not. The study suggests that maintaining stable cholesterol levels is crucial for brain health.

Perinatal pathologists advocate for placental pathology in clinical trials to improve understanding of pregnancy-related conditions. Mana Parast, UC San Diego, highlights the under-investigation of placenta, suggesting it mirrors cancer staging. Placental pathology could guide preventive therapies and classify preeclampsia types. Challenges include lack of funding, trained pathologists, and clinical relevance understanding. Advocacy groups support standardizing placental pathology reports to enhance clinical utility and research funding.